Biomerics recently announced that it has acquired FutureMatrix Interventional. The financial details of the deal were not disclosed.
FutureMatrix Interventional (Athens, Texas) specializes in the design and manufacture of interventional catheters for the cardiovascular and urinary markets. Founded in 1993, the company starts as a developer of PTA catheters. It expanded into PTA balloon technologies over the years and began to develop peripheral cardiovascular, kidney stone management and urinary catheters. FutureMatrix Interventional employs more than 400 employees and has over 50,000 sq. ft of manufacturing space.
“We are pleased to add FMI’s capabilities to the Biomerics portfolio,” Travis Sessions, CEO of Biomerics, said in a press release. “We welcome the FMI team to the group and look forward to their contribution. This acquisition expands our capabilities and important customer relationships. We look forward to investing in and expanding the business for our customers, employees and community. Combining FMI with Biomerics’ existing medical device business establishes Biomerics as a leader in the attractive minimally invasive interventional segment of the medical device market.”
Biomerics employs over 1,000 people in seven facilities in Utah, Minnesota, Indiana, Costa Rica and Texas. It currently develops minimally invasive interventional catheters and provides engineered components to the medical device market, including biomaterials, extrusions, molded parts, laser processed parts, machined parts, balloons and reinforced shafts. It also supplies packaged sterile medical devices like advanced interventional catheters, surgical tools and vascular access products.
